(BBLG) Bone Biologics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0980703039

BBLG: Protein, Bone Graft, Surgical Implants, Medical Devices

Bone Biologics Corporation (NASDAQ:BBLG) is a medical device company specializing in bone regeneration technologies, primarily targeting spinal fusion applications. The companys lead product, NELL-1/DBM, is an osteopromotive recombinant protein designed to enhance bone regeneration with precise control. This technology is central to the development of the NELL-1/DBM Fusion Device, intended for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease affecting the L2-S1 spinal segments. Beyond spinal applications, the platform technology has potential utility across surgical specialties, including orthopedics, neurosurgery, and sports medicine.

Bone Biologics holds a license agreement with the UCLA Technology Development Group to commercialize NELL-1 for spinal fusion applications, underscoring its collaborative approach to innovation. Founded in 2004 and headquartered in Burlington, Massachusetts, the company operates in a niche segment of the medical device industry focused on addressing unmet needs in bone repair and regeneration.

3-Month Forecast: Based on and , BBLG is expected to face headwinds in the near term. The stock is currently trading below its 20-day and 50-day moving averages, with a last price of $0.84 compared to the SMA 20 at $0.94 and SMA 50 at $1.00. This indicates bearish momentum. However, the ATR of $0.09 suggests low volatility, which may limit downside risks. From a perspective, the companys market cap of $2.75M and P/B ratio of 0.79 indicate a small, potentially undervalued entity, though the absence of meaningful revenue and profitability metrics raises concerns about its growth trajectory. Over the next three months, BBLGs performance will likely hinge on clinical trial progress or regulatory updates, which could serve as catalysts for price movement.

Additional Sources for BBLG Stock

BBLG Stock Overview

Market Cap in USD 3m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 2016-03-31

BBLG Stock Ratings

Growth 5y -77.8%
Fundamental -8.36%
Dividend 0.0%
Rel. Strength Industry -67.7
Analysts 5/5
Fair Price Momentum 0.75 USD
Fair Price DCF -

BBLG Dividends

No Dividends Paid

BBLG Growth Ratios

Growth Correlation 3m -46.6%
Growth Correlation 12m -71.4%
Growth Correlation 5y -98.8%
CAGR 5y -90.03%
CAGR/Max DD 5y -0.90
Sharpe Ratio 12m -1.40
Alpha -75.37
Beta 0.83
Volatility 156.94%
Current Volume 18.1k
Average Volume 20d 95.4k
What is the price of BBLG stocks?
As of March 14, 2025, the stock is trading at USD 0.83 with a total of 18,147 shares traded.
Over the past week, the price has changed by -1.52%, over one month by -19.68%, over three months by -26.13% and over the past year by -67.81%.
Is Bone Biologics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Bone Biologics is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -8.36 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBLG as of March 2025 is 0.75. This means that BBLG is currently overvalued and has a potential downside of -9.64%.
Is BBLG a buy, sell or hold?
Bone Biologics has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy BBLG.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for BBLG stock price target?
According to ValueRays Forecast Model, BBLG Bone Biologics will be worth about 0.8 in March 2026. The stock is currently trading at 0.83. This means that the stock has a potential upside of +1.2%.
Issuer Forecast Upside
Wallstreet Target Price 16.5 1888%
Analysts Target Price 37.8 4448.2%
ValueRay Target Price 0.8 1.2%